$0.65 EPS Expected for Abbott Laboratories (ABT)

September 17, 2017 - By Adrian Erickson

 $0.65 EPS Expected for Abbott Laboratories (ABT)
Investors sentiment increased to 1.01 in 2016 Q4. Its up 0.05, from 0.96 in 2016Q3. It is positive, as 83 investors sold Abbott Laboratories shares while 496 reduced holdings. 103 funds opened positions while 481 raised stakes. 1.06 billion shares or 1.63% more from 1.04 billion shares in 2016Q3 were reported.
Regentatlantic Capital Ltd Limited Liability Company holds 36,455 shares or 0.14% of its portfolio. 34,946 are owned by Klingenstein Fields & Co Limited Co. Hilltop Inc accumulated 12,553 shares or 0.15% of the stock. Stonebridge Inc has invested 0.3% of its portfolio in Abbott Laboratories (NYSE:ABT). Independent Franchise Prns Ltd Liability Partnership accumulated 9.95 million shares or 3.84% of the stock. Moreover, Louisiana State Employees Retirement System has 0.18% invested in Abbott Laboratories (NYSE:ABT) for 92,600 shares. 229,857 were reported by Dalton Greiner Hartman Maher &. 24,705 are owned by Peoples Financial Service. Indiana Inv has 18,806 shares. Garrison Bradford And Assoc Inc, New York-based fund reported 5,400 shares. Ftb Advsrs reported 0.37% of its portfolio in Abbott Laboratories (NYSE:ABT). New Vernon Investment Limited Com holds 14,107 shares. Tekla Management Llc stated it has 1.58M shares or 2.59% of all its holdings. Harvey Invest Ltd Com invested in 247,301 shares. Jarislowsky Fraser Limited reported 2.32M shares stake.

Since March 31, 2017, it had 0 buys, and 2 sales for $60,722 activity. Contreras Jaime had sold 767 shares worth $34,240 on Friday, March 31.

Wall Street await Abbott Laboratories (NYSE:ABT) to release earnings on October, 18. Analysts forecast earnings per share of $0.65, up exactly $0.06 or 10.17 % from 2014’s $0.59 EPS. The expected ABT’s profit could reach $1.13 billion giving the stock 19.91 P/E in the case that $0.65 earnings per share is reported. After posting $0.62 EPS for the previous quarter, Abbott Laboratories’s analysts now forecast 4.84 % EPS growth. The stock increased 0.12% or $0.06 on September 15, reaching $51.76. About 6.70 million shares traded or 45.02% up from the average. Abbott Laboratories (NYSE:ABT) has risen 15.90% since September 17, 2016 and is uptrending. It has underperformed by 0.80% the S&P500.

Abbott Laboratories (NYSE:ABT) Ratings Coverage

Among 23 analysts covering Abbott Laboratories (NYSE:ABT), 14 have Buy rating, 0 Sell and 9 Hold. Therefore 61% are positive. Abbott Laboratories had 70 analyst reports since July 24, 2015 according to SRatingsIntel. Stifel Nicolaus maintained Abbott Laboratories (NYSE:ABT) on Thursday, July 20 with “Buy” rating. As per Thursday, July 14, the company rating was maintained by Jefferies. The rating was maintained by BTIG Research with “Buy” on Saturday, August 29. The firm has “Equal-Weight” rating by Morgan Stanley given on Monday, January 4. The firm has “Outperform” rating by RBC Capital Markets given on Thursday, July 23. The rating was maintained by Deutsche Bank with “Buy” on Friday, July 21. The firm has “Buy” rating given on Friday, July 21 by Gabelli. The rating was maintained by RBC Capital Markets with “Outperform” on Friday, October 9. The stock has “Buy” rating by Argus Research on Friday, February 5. The stock has “Outperform” rating by RBC Capital Markets on Thursday, January 26.

Abbott Laboratories is engaged in the discovery, development, manufacture and sale of a range of healthcare products. The company has market cap of $89.93 billion. The Firm operates through four divisions: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. It has a 79.47 P/E ratio. The Company’s Established Pharmaceutical Products include a range of branded generic pharmaceuticals manufactured around the world and marketed and sold outside the United States.

More notable recent Abbott Laboratories (NYSE:ABT) news were published by: Investorplace.com which released: “3 Big Stock Charts for Tuesday: Abbott Laboratories (ABT), Aetna Inc (AET) and …” on September 12, 2017, also Reuters.com with their article: “BRIEF-Abbott Laboratories says ‍NHS Business Services Authority approved …” published on September 13, 2017, Nasdaq.com published: “Why Is Abbott Laboratories (ABT) Down 3.1% Since the Last Earnings Report?” on August 21, 2017. More interesting news about Abbott Laboratories (NYSE:ABT) were released by: Chicagotribune.com and their article: “Abbott releases software fixes for heart devices that could be hacked” published on August 30, 2017 as well as Seekingalpha.com‘s news article titled: “Can Abbott Top Its All-Time High?” with publication date: September 07, 2017.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.